Crossmark

Eltrombopag as initial monotherapy for severe aplastic anemia—a case report

Crossref DOI link: https://doi.org/10.1007/s00277-018-3303-z

Published Online: 2018-03-20

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Rodgers, George M.

Gilreath, Jeffrey A.
License Information

Text and Data Mining valid from 2018-03-20
More Information

Article History

Received: 9 January 2018

Accepted: 12 March 2018

First Online: 20 March 2018

Compliance with ethical standards

:

: G. Rodgers is on the speaker’s bureau of Novartis. J. Gilreath has no relevant conflicts of interest to report.